Results 51 to 60 of about 27,057 (223)

The diagnosis and management of the haematologic manifestations of lupus [PDF]

open access: yes, 2016
Haematological manifestations in systemic lupus erythematosus (SLE) are frequently observed. They are diverse and range from mild to severe.
Castro, SG   +2 more
core   +1 more source

Refractory gout in primary myelofibrosis [PDF]

open access: yesBlood, 2019
![Figure][1] A 66-year-old man from the Dominican Republic presented to the Myeloproliferative Neoplasms Clinic at Mount Sinai with a 10-year history of untreated JAK2V617F- positive primary myelofibrosis (PMF).
Sangeetha Venugopal, John Mascarenhas
openaire   +2 more sources

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson   +4 more
wiley   +1 more source

Analysis of MicroRNA -155-5p Expression in Patients with Primary Myelofibrosis.

open access: yesمجلة كلية الطب
Background: Primary myelofibrosis is a chronic myeloproliferative neoplasm characterized by abnormal megakaryocyte proliferation and fibrosis that destroys healthy bone marrow.
Sarah I. Khaleel   +1 more
doaj   +1 more source

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

open access: yesHaematologica, 2011
Background The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under ...
Brady L. Stein   +9 more
doaj   +1 more source

Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects [PDF]

open access: yes, 2010
Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms (MPN), according to the 4th edition of the World Health Organization (WHO) classification are clonal diseases of hematopoietic stem cells, in which there is increased ...
Chauffaille, Maria de Lourdes Lopes Ferrari
core   +1 more source

On‐Scanner Correction of Gradient Nonlinearity Bias for Accurate Assessment of Diffusion Heterogeneity Across Bone Sites in Myelofibrosis Patients

open access: yesMagnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose To improve accuracy of apparent diffusion coefficient (ADC) measurement across different bone‐marrow (BM) sites for myelofibrosis (MF) patients. Methods Vendor‐provided ADC gradient nonlinearity correction (GNC) was implemented for 41 MF study subjects on a 3T clinical scanner.
Dariya Malyarenko   +9 more
wiley   +1 more source

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

open access: yesHematology, Transfusion and Cell Therapy, 2018
Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro   +11 more
doaj   +1 more source

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. [PDF]

open access: yes, 2018
Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Aungier, Juliet   +17 more
core   +1 more source

Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene‐CanVar and the NHS England Haematological Oncology Working Group

open access: yesBritish Journal of Haematology, EarlyView.
Summary Genomic technologies including next‐generation sequencing (NGS) and arrays for cytogenetic anomalies are now standard of care in England for the diagnostic evaluation of patients with suspected haematological malignancies. Challenges remain in the management of potential germline findings as a result of NGS panels and copy number variant ...
B. Speight   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy